Protara Therapeutics, Inc. (TARA)

Protara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	18.14	18.62	20.74	26.4	22.46	3.95
Research & Development	27.59	24.99	16.81	21.09	11.98	3.88
Other Operating Expenses	0	0	29.52	0	0	0
Operating Expenses	45.73	43.61	67.06	47.49	34.44	7.83
Operating Income	-45.73	-43.61	-67.06	-47.49	-34.44	-7.83
Interest Expense / Income	0	0	0	0	0.03	0
Other Expense / Income	-3.26	-3.19	-1.11	-0.24	-0.5	-
Pretax Income	-42.47	-40.42	-65.95	-47.25	-33.98	-7.83
Net Income	-42.47	-40.42	-65.95	-47.25	-33.98	-7.83
Shares Outstanding (Basic)	11	11	11	11	7	3
Shares Outstanding (Diluted)	11	11	11	11	7	3
Shares Change	1.04%	0.64%	0.24%	55.28%	180.66%	469.54%
EPS (Basic)	-3.74	-3.57	-5.86	-4.21	-4.70	-3.04
EPS (Diluted)	-3.74	-3.57	-5.86	-4.21	-4.70	-3.04
Free Cash Flow	-35.09	-37.6	-26.58	-35.1	-24.29	-5.49
Free Cash Flow Per Share	-3.07	-3.32	-2.36	-3.13	-3.36	-2.13
EBITDA	-42.12	-40.08	-65.7	-47.14	-33.84	-7.81
Depreciation & Amortization	0.35	0.34	0.25	0.12	0.1	0.02
EBIT	-42.47	-40.42	-65.95	-47.25	-33.94	-7.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).